Glenmark’s stock rises as Swiss unit secures Hengrui’s trastuzumab rezetecan licence, boosting outlook for investors.

• Deal includes $18 million upfront and up to $1.09 billion in milestone payments for Hengrui drug rights
• Nomura predicts the drug will drive Glenmark’s $350‑400 million innovation revenue target over the next five years alone
• Analysts rate Glenmark “buy”; median price target 2,400 rupees, stock up 27% YTD 2025 so far